Glenmark Pharma launches Rufinamide tablets:

Glenmark

Glenmark Pharmaceuticals has launched Rufinamide Tablets USP, 200 mg and 400 mg, a therapeutic equivalent of Banzel Tablets, 200 mg and 400 mg of Eisai, Inc.

Glenmark was one of the first ANDA applicants to submit a substantially complete ANDA for Rufinamide Tablets USP, 200 mg and 400 mg, with a paragraph IV certification and received final approval on May 16, 2016, company said in its release.

Glenmark Pharma was quoting at Rs 595.05, up Rs 2.45, or 0.41 percent on the BSE.

News source:- Moneycontrol

For Enquiry Fill The Form

*Note:- Please provide a valid Email Id to receive OTP from bigprofitbuzz.com.

Facebook Iconfacebook like buttonYouTube IconTwitter Icontwitter follow button